• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Paratek Pharmaceuticals Inc.

    5/18/22 4:47:08 PM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTK alert in real time by email
    SC 13G 1 prtk13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Paratek Pharmaceuticals, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001

    (Title of Class of Securities)

     

     

    699374302

    (CUSIP Number)

     

     

    May 9, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 699374302

     

    1.Names of Reporting Persons.

    Laurence W. Lytton

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization USA

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 3,209,552

     

    6. Shared Voting Power 1,000

     

    7. Sole Dispositive Power 3,209,552
    8. Shared Dispositive Power 1,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 3,210,552

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.9%

     

    12.Type of Reporting Person (See Instructions) IN

     

     2 
    CUSIP No. 699374302

    Item 1.

     

    (a)Name of Issuer

    Paratek Pharmaceuticals, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    75 Park Plaza, Boston, MA 02116

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Laurence W. Lytton

    (b)The principal business office of the Filers is located at:

    467 Central Park West
    New York, NY 10025

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to shares of Common Stock, par value $0.001 of the Issuer (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 699374302
     3 
    CUSIP No. 699374302
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     4 
    CUSIP No. 699374302

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: May 18, 2022

     

     

    ___/s/ Laurence W. Lytton____________________

    Laurence W. Lytton

     

     

     

    Get the next $PRTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRTK

    DatePrice TargetRatingAnalyst
    5/2/2023$7.00 → $5.00Buy
    Jefferies
    4/17/2023$24.00Buy
    BTIG Research
    2/10/2022$11.00Buy → Strong Buy
    WBB Securities
    11/9/2021$28.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PRTK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NUZYRA issued to PARATEK PHARMS INC

      Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy

      5/31/21 5:18:25 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NUZYRA issued to PARATEK PHARMS INC

      Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy

      5/31/21 5:18:25 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NUZYRA

      Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209817, Application Classification: Labeling

      1/26/21 5:26:59 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTK
    Financials

    Live finance-specific insights

    See more
    • Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

      -- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ("Paratek" or "the Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today reported financial results and provided an update on corpora

      8/3/23 8:00:00 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million

      -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats fo

      5/9/23 4:05:00 PM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9

      BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9About Paratek Phar

      5/1/23 8:30:00 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

      CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structu

      9/21/23 8:58:57 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

      BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek's special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with th

      9/18/23 9:37:40 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

      BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading independent proxy advisor Glass, Lewis & Co. ("Glass Lewis") has recommended that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). The Glass Lewis recommendation follows the recent receipt of the recommendation from Institutional Shareholder Services Inc. (

      9/12/23 7:30:00 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTK
    Leadership Updates

    Live Leadership Updates

    See more
    • Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

      BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of Paratek and the business of the anti-infective industry, strong financial and operational track record, and demonstrated independent judgment, integrity and commitment to the role. Having served as a director of Paratek since its emergence as a public company in 2014, Dr. Stein

      12/20/22 7:30:00 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

      NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

      3/1/22 4:05:00 PM ET
      $APYX
      $LNTH
      $PRTK
      $SCPH
      Medical/Dental Instruments
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Pharmaceutical Preparations
    • Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management

      - Evan Loh, M.D., Jonathan Leff, and Jana Jensen, Ph.D., Appointed Directors of APT - Adaptive Phage Therapeutics, Inc. ("APT"), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company's Board of Directors. "We are delighted to welcome Evan, Jonathan, and Jana to APT's Board, as we expand our team following the successful completion of our $40.75 million Series B financing," said Greg Merril, A

      6/29/21 8:00:00 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTK
    SEC Filings

    See more
    • SEC Form 15-12G filed by Paratek Pharmaceuticals Inc.

      15-12G - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)

      10/2/23 7:33:56 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Paratek Pharmaceuticals Inc.

      EFFECT - Paratek Pharmaceuticals, Inc. (0001178711) (Filer)

      9/26/23 12:15:16 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13E3/A filed by Paratek Pharmaceuticals Inc. (Amendment)

      SC 13E3/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)

      9/21/23 10:59:30 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Baylor-Henry Minnie returned 59,200 shares to the company, closing all direct ownership in the company

      4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)

      9/21/23 1:24:36 PM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Hoffmann Rolf K returned 84,000 shares to the company, closing all direct ownership in the company

      4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)

      9/21/23 1:24:04 PM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Brenner Randall B. returned 415,209 shares to the company, closing all direct ownership in the company

      4 - Paratek Pharmaceuticals, Inc. (0001178711) (Issuer)

      9/21/23 1:23:46 PM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies resumed coverage on Paratek Pharma with a new price target

      Jefferies resumed coverage of Paratek Pharma with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      5/2/23 9:03:21 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research resumed coverage on Paratek Pharma with a new price target

      BTIG Research resumed coverage of Paratek Pharma with a rating of Buy and set a new price target of $24.00

      4/17/23 9:07:06 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Paratek Pharmaceuticals upgraded by WBB Securities with a new price target

      WBB Securities upgraded Paratek Pharmaceuticals from Buy to Strong Buy and set a new price target of $11.00

      2/10/22 7:13:20 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Paratek Pharmaceuticals Inc.

      SC 13G - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)

      9/5/23 5:03:06 PM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Paratek Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)

      6/27/23 8:20:26 AM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Paratek Pharmaceuticals Inc.

      SC 13D - Paratek Pharmaceuticals, Inc. (0001178711) (Subject)

      3/30/23 4:30:07 PM ET
      $PRTK
      Biotechnology: Pharmaceutical Preparations
      Health Care